ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03362151
Recruitment Status : Recruiting
First Posted : December 5, 2017
Last Update Posted : January 29, 2018
Sponsor:
Collaborator:
Harvard University
Information provided by (Responsible Party):
Sansum Diabetes Research Institute

Brief Summary:
The aim of this clinical study is to investigate and compare the postprandial glycemic response to three different meal types rich in carbohydrates, that is, white pasta, high protein pasta and white rice consumed by individuals with T1DM.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Other: Regular pasta Other: High protein pasta Other: White rice Not Applicable

Detailed Description:

The aim of this clinical study is to investigate and compare the postprandial glycemic response to three different meal types rich in carbohydrates, that is, white pasta, high protein pasta and white rice consumed by individuals with T1DM and to demonstrate that:

  1. The choice of carbohydrates consumed significantly affects the postprandial glycemic profile in people with type 1 diabetes and
  2. The consumption of high protein pasta will present a tighter postprandial glycemic response.

Previous studies have evaluated the effect of white pasta and rice on postprandial glycemic response in people with type 1 diabetes. With this study, we aim to expand upon these findings by ensuring that the results can still be applied to more recent commercial food products (pasta, rice), but especially to evaluate the effect of high-protein pasta when compared to regularly consumed carbohydrates (white pasta, white rice).

After consuming the study meal, subjects will participate in an education session (a 2 hour class per each meal challenge session). Classes will be taught by a registered dietician and diabetes & exercise expert and, as appropriate, a culinary instructor.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

Subjects will consume pre-determined meals on 6 difference occasions. There will be three categories of "study meals" consisting of:

  1. Regular pasta (42 grams carbohydrate per meal)
  2. High protein pasta (38 grams carbohydrate per meal)
  3. White rice (43 grams carbohydrate per meal)

Each subject will consume each meal on two separate occasions in random order.

Masking: Double (Participant, Investigator)
Masking Description: Subjects will not be told which meal they are eating.
Primary Purpose: Treatment
Official Title: A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : August 1, 2018
Estimated Study Completion Date : December 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Regular pasta
Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of regular pasta. They will consume this meal on two separate occasions.
Other: Regular pasta
Regular pasta (Approximately 42 grams carbohydrate per meal)

Experimental: High protein pasta
Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of high protein pasta. They will consume this meal on two separate occasions.
Other: High protein pasta
High protein pasta (Approximately 38 grams carbohydrate per meal)

Experimental: White rice
Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of white rice. They will consume this meal on two separate occasions.
Other: White rice
White rice (Approximately 43 grams carbohydrate per meal)




Primary Outcome Measures :
  1. Delta glucose (maximum rise from baseline glucose) mg/dL [ Time Frame: 5 hours ]
    Delta glucose (maximum rise from baseline glucose) from the start of the meal to the peak continuous glucose monitoring (CGM) glucose reading (mg/dL) during the 5-hour postprandial window, compared between the three meal types.


Secondary Outcome Measures :
  1. Incremental area under the curve (area) [ Time Frame: 5 hours ]
    Incremental area under the curve (iAUC) glucose level for the 5 hour postprandial period adjusted for baseline glucose at the start of the meal.

  2. Time to peak glucose level (minutes) [ Time Frame: 5 hours ]
    Time to peak glucose level (in minutes from intervention)

  3. percent time glucose <70 mg/dL [ Time Frame: 5 hours ]
    In case of postprandial hypoglycemia, percent time glucose <70 mg/dL for the 5 hour postprandial period will be evaluated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 and ≤ 75 years at the time of screening.
  • Clinical diagnosis of type 1 diabetes for at least one year.
  • HbA1c ≤ 10%, as performed by point of care or central laboratory testing. A1c will be assessed at the screening visit, or if already completed within 2 months of the screening visit, the prior lab value may be used in lieu of repeating this assessment.
  • Currently using insulin-to-carbohydrate ratio to calculate meal bolus sizes, and boluses for all meals and snacks that contain ≥ 5 grams of carbohydrate.
  • Willing to refrain from taking acetaminophen products for the duration of the clinical trial. If acetaminophen is taken, subject is to avoid making any insulin dosing decisions based on CGM for at least 12 hours.
  • For females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative urine pregnancy test will be required for all premenopausal women who are not surgically sterile at the screening visit. Subjects who become pregnant will be discontinued from the study.
  • Willing to abide by the study protocol and use study-provided devices.

Exclusion Criteria:

  • Gastrointestinal disease such as celiac disease or multiple food allergies.
  • Any form of gluten sensitivity or wheat allergy.
  • Allergies to any form of nuts and ingredients present in the study meals (tomatoes etc).
  • History of gastroparesis.
  • Pregnancy.
  • Dermatological conditions that would preclude wearing a CGM sensor.
  • Screening A1c > 10%.
  • Any condition that could interfere with participating in the trial, based on the investigator's judgment.
  • A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol.
  • Participation in another pharmaceutical or device trial at the time of enrollment or during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362151


Contacts
Contact: Jennifer Massa 617-432-3276 jmassa@hsph.harvard.edu

Locations
United States, California
Sansum Diabetes Research Institute Recruiting
Santa Barbara, California, United States, 93105
Contact: Camille Andre    805-682-7640 ext 217    candre@sansum.org   
Principal Investigator: Jordan E Pinsker, MD         
Sub-Investigator: Mei Mei Church, NP         
Sponsors and Collaborators
Sansum Diabetes Research Institute
Harvard University
Investigators
Principal Investigator: David Eisenberg, MD Harvard T.H. Chan School of Public Health
Principal Investigator: Eyal Dassau, PhD Harvard John A. Paulson School of Engineering and Applied Sciences
Principal Investigator: Jordan E Pinsker, MD Sansum Diabetes Research Institute

Responsible Party: Sansum Diabetes Research Institute
ClinicalTrials.gov Identifier: NCT03362151     History of Changes
Other Study ID Numbers: IRB17-1316
First Posted: December 5, 2017    Key Record Dates
Last Update Posted: January 29, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Sansum Diabetes Research Institute:
type 1 diabetes
pasta
rice
protein
carbohydrate

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases